Latest Lilly job cuts target marketing employees

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. informed another 200 employees Friday that their jobs are being eliminated, including more than 100 in the Indianapolis area.

The jobs are marketing positions in Lilly’s biomedicines unit, which includes Lilly’s bestselling drugs, such as the antipsychotic Zyprexa and the antidepressant Cymbalta. The affected employees can apply for other jobs within Lilly—although there are a limited number of open positions.

The latest cuts are part of Lilly’s plans, announced in September, to trim 5,500 jobs from its payroll by the end of 2011. In April, Lilly said it had eliminated 1,500 jobs so far. Friday’s job cuts appear to be in addition to that total, but a Lilly spokesman would not confirm that.

Lilly is making more money than ever right now, but beginning in October 2011, the patents on its besetselling drugs will begin to expire, threatening to drain the company of roughly half its current revenue by 2015.

When Lilly announced its restructuring plan last year, it employed about 40,500 workers worldwide. However, it is also increasing hiring in China and other “strategic” areas. As of March 31, Lilly’s work force totaled 39,380.

“Work force reductions will be ongoing throughout the next several months in order to meet the company's publicly stated goals announced in Sept. 2009,” Lilly spokesman Ed Sagebiel wrote in an e-mail.

Previous layoff announcements have impacted laboratory researchers, sales representatives and manufacturing—including the transfer of the manufacturing plant in Lafayette to Germany-based Evonik Industries AG.

Lilly is providing outplacement and job search help to all employees who lose their jobs and do not find new ones at the company.

More details about Lilly’s restructuring plan can be found here.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ